Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations

Bart Koopman, Harry J.M. Groen, Marjolijn J.L. Ligtenberg, Katrien Grünberg, Kim Monkhorst, Adrianus J. de Langen, Mirjam C. Boelens, Marthe S. Paats, Jan H. von der Thüsen, Winand N.M. Dinjens, Nienke Solleveld, Tom van Wezel, Hans Gelderblom, Lizza E. Hendriks, Ernst Jan M. Speel, Tom E. Theunissen, Leonie I. Kroeze, Niven Mehra, Berber Piet, Anthonie J. van der WekkenArja ter Elst, Wim Timens, Stefan M. Willems, Ruud W.J. Meijers, Wendy W.J. de Leng, Anne S.R. van Lindert, Teodora Radonic, Sayed M.S. Hashemi, Daniëlle A.M. Heideman, Ed Schuuring, Léon C. van Kempen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)
13 Downloads (Pure)

Abstract

Background: Molecular tumor boards (MTBs) provide rational, genomics-driven, patient-tailored treatment recommendations. Worldwide, MTBs differ in terms of scope, composition, methods, and recommendations. This study aimed to assess differences in methods and agreement in treatment recommendations among MTBs from tertiary cancer referral centers in The Netherlands. Materials and Methods: MTBs from all tertiary cancer referral centers in The Netherlands were invited to participate. A survey assessing scope, value, logistics, composition, decision-making method, reporting, and registration of the MTBs was completed through on-site interviews with members from each MTB. Targeted therapy recommendations were compared using 10 anonymized cases. Participating MTBs were asked to provide a treatment recommendation in accordance with their own methods. Agreement was based on which molecular alteration(s) was considered actionable with the next line of targeted therapy. Results: Interviews with 24 members of eight MTBs revealed that all participating MTBs focused on rare or complex mutational cancer profiles, operated independently of cancer type–specific multidisciplinary teams, and consisted of at least (thoracic and/or medical) oncologists, pathologists, and clinical scientists in molecular pathology. Differences were the types of cancer discussed and the methods used to achieve a recommendation. Nevertheless, agreement among MTB recommendations, based on identified actionable molecular alteration(s), was high for the 10 evaluated cases (86%). Conclusion: MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational cancer profiles. We propose a “Dutch MTB model” for an optimal, collaborative, and nationally aligned MTB workflow. Implications for Practice: Interpretation of genomic analyses for optimal choice of target therapy for patients with cancer is becoming increasingly complex. A molecular tumor board (MTB) supports oncologists in rationalizing therapy options. However, there is no consensus on the most optimal setup for an MTB, which can affect the quality of recommendations. This study reveals that the eight MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational profiles. The Dutch MTB model is based on a collaborative and nationally aligned workflow with interinstitutional collaboration and data sharing.

Original languageEnglish
Pages (from-to)e1347-e1358
JournalOncologist
Volume26
Issue number8
DOIs
Publication statusPublished - 28 Oct 2020

Bibliographical note

Acknowledgments:
We are grateful to Anke van den Berg, Matthew Groves, Geke Hospers, Birgitta Hiddinga, Hilde Jalving, Lucie Hijmering‐Kappelle, Joost Kluiver, Michel van Kruchten, Elise van der Logt, Maarten Niemantsverdriet, Sjoukje Oosting, Juliana Vilacha, Michel van den Heuvel, Lieneke Steeghs, Ingrid Vogelaar, Linda Bosch, Liudmila Kodach, Egbert Smit, Annette Bijsmans, Maxime van Berge Henegouwen, Hans Morreau, Lisa Hillen, Xiao Fei Li, John Hinrichs, Anne Jansen, Joyce Radersma‐van Loon, and Aryan Vink and all other members of the molecular tumor boards in The Netherlands for their contributions to the conduct and successful completion of this study. This work was supported by ZonMW (The Netherlands Organization for Health Research) within the Personalized Medicine Program (grant number 846001001).

Publisher Copyright:
© 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.

Fingerprint

Dive into the research topics of 'Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations'. Together they form a unique fingerprint.

Cite this